Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11042)
All Articles published online
|
Publishing Process of This Article
|
Sep 14, 2016 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5330/full/v22/i34/7727.htm |
| Number | Citing Articles |
| 1 |
Ziwei Li, Jun Zhang, Yufeng Zhang, Limin Zhou, Jiajia Zhao, Yuanfeng Lyu, Long Hin Poon, Zhixiu Lin, Kenneth Kin Wah To, Xiaoyu Yan, Zhong Zuo. Intestinal absorption and hepatic elimination of drugs in high‐fat high‐cholesterol diet‐induced non‐alcoholic steatohepatitis rats: exemplified by simvastatin. British Journal of Pharmacology 2021; 178(3): 582 doi: 10.1111/bph.15298
|
| 2 |
Tingyu Dong, Jiajin Li, Yuqing Liu, Shikai Zhou, Xiang Wei, Hongting Hua, Kechao Tang, Xiaomin Zhang, Yiming Wang, Zhen Wu, Chaobing Gao, Huabing Zhang. Roles of immune dysregulation in MASLD. Biomedicine & Pharmacotherapy 2024; 170: 116069 doi: 10.1016/j.biopha.2023.116069
|
| 3 |
Kanishk Aggarwal, Bhupinder Singh, Abhishek Goel, Durgesh Kumar Agrawal, Sourav Bansal, Sai Gautham Kanagala, Fnu Anamika, Aachal Gupta, Rohit Jain. Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities. Intestinal Research 2024; 22(4): 414 doi: 10.5217/ir.2024.00001
|
| 4 |
Qianqian Yao, Yanan Gao, Linlin Fan, Jiaqi Wang, Nan Zheng. 2′-Fucosyllactose Remits Colitis-Induced Liver Oxygen Stress through the Gut–Liver–Metabolites Axis. Nutrients 2022; 14(19): 4186 doi: 10.3390/nu14194186
|
| 5 |
Yanlin Zhu, Shuangshuang Xu, Yi Lu, Yijuan Wei, Benqiang Yao, Fusheng Guo, Xing Zheng, Yumeng Wang, Ying He, Lihua Jin, Yong Li. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00590
|
| 6 |
Wenxin Wang, Xin Gao, Ning Kang, Chen Wang, Chenyang Li, Huan Yu, Xiaolan Zhang. Shared biomarkers and immune cell infiltration signatures in ulcerative colitis and nonalcoholic steatohepatitis. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-44853-6
|
| 7 |
Extraintestinal manifestations of inflammatory bowel disease, nitroxidative stress and dysbiosis: What is the link between them?. BIOCELL 2021; 45(3): 461 doi: 10.32604/biocell.2021.014332
|
| 8 |
Elisa Carolina Lange, Pabulo Henrique Rampelotto, Larisse Longo, Laura Bainy Rodrigues de Freitas, Carolina Uribe-Cruz, Mario Reis Alvares-da-Silva. Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease. World Journal of Hepatology 2024; 16(5): 832-842 doi: 10.4254/wjh.v16.i5.832
Abstract(205) |
Core Tip(191) |
Full Article(HTML)(918)
|
Full Article with Cover (PDF)-5433K(57)
|
Audio-840K(5)
|
Peer-Review Report-176K(24)
|
Answering Reviewers-106K(21)
|
Supplementary Material-395K(27)
|
Full Article (PDF)-2439K(62)
|
Full Article (XML)-96K(27)
|
Times Cited (0)
|
Total Visits (3002)
|
Open
|
| 9 |
Sophie Restellini, Olivier Chazouillères, Jean‐Louis Frossard. Hepatic manifestations of inflammatory bowel diseases. Liver International 2017; 37(4): 475 doi: 10.1111/liv.13265
|
| 10 |
Justyna Kikut, Nina Konecka, Maciej Ziętek, Małgorzata Szczuko. Inflammatory Bowel Disease Etiology: Current Knowledge. Pteridines 2018; 29(1): 206 doi: 10.1515/pteridines-2018-0020
|
| 11 |
Shu Liang, Yupei Zhang, Yuanjun Deng, Yifang He, Yinji Liang, Zien Liang, Yanning Chen, Kairui Tang, Runsen Chen, Qinhe Yang, Kamal D. Moudgil. The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota. Evidence-Based Complementary and Alternative Medicine 2018; 2018(1) doi: 10.1155/2018/5378961
|
| 12 |
Ludovico Abenavoli, Rocco Spagnuolo, Giuseppe Guido Maria Scarlata, Maria Luisa Gambardella, Luigi Boccuto, Nahum Méndez-Sánchez, Francesco Luzza. Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study. Life 2024; 14(10): 1226 doi: 10.3390/life14101226
|
| 13 |
Konstantinos Arvanitakis, Theocharis Koufakis, Djordje Popovic, Giuseppe Maltese, Omar Mustafa, Michael Doumas, Olga Giouleme, Kalliopi Kotsa, Georgios Germanidis. GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. Current Obesity Reports 2023; 12(2): 61 doi: 10.1007/s13679-023-00506-3
|
| 14 |
Shaya Noorian, Yejoo Jeon, Minh T Nguyen, Jenny Sauk, Berkeley N Limketkai. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflammatory Bowel Diseases 2022; 28(6): 878 doi: 10.1093/ibd/izab199
|
| 15 |
Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras, Stergios A Polyzos. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis 2022; 16(5): 852 doi: 10.1093/ecco-jcc/jjab212
|
| 16 |
Katerina Karaivazoglou, Christos Konstantakis, Evanthia Tourkochristou, Stelios F. Assimakopoulos, Christos Triantos. Non-alcoholic fatty liver disease in inflammatory bowel disease patients. European Journal of Gastroenterology & Hepatology 2020; 32(8): 903 doi: 10.1097/MEG.0000000000001679
|
| 17 |
Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen, Wan-Long Chuang. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study. PLOS ONE 2021; 16(5): e0252286 doi: 10.1371/journal.pone.0252286
|
| 18 |
Takahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, Satoshi Shakado, Keiji Yokoyama, Kazuhide Takata, Takashi Tanaka, Atsushi Fukunaga, Ryo Yamauchi, Hiromi Fukuda, Hiroki Matsuoka, So Imakiire, Hideto Sakisaka, Satoshi Matsuoka, Nobuaki Kuno, Koichi Abe, Hideki Ishibashi, Shinya Ashizuka, Fumihito Hirai. Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study. Intestinal Research 2023; 21(4): 471 doi: 10.5217/ir.2023.00035
|
| 19 |
Giovanni E. Lombardo, Michele Navarra, Eleonora Cremonini. A flavonoid-rich extract of bergamot juice improves high-fat diet-induced intestinal permeability and associated hepatic damage in mice. Food & Function 2024; 15(19): 9941 doi: 10.1039/D4FO02538E
|
| 20 |
Cholsoon Jang, Shogo Wada, Steven Yang, Bridget Gosis, Xianfeng Zeng, Zhaoyue Zhang, Yihui Shen, Gina Lee, Zoltan Arany, Joshua D. Rabinowitz. The small intestine shields the liver from fructose-induced steatosis. Nature Metabolism 2020; 2(7): 586 doi: 10.1038/s42255-020-0222-9
|
| 21 |
Yunfei Luo, Hui Lin. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immunity, Inflammation and Disease 2021; 9(1): 59 doi: 10.1002/iid3.391
|
| 22 |
Chungho Lee, SangAh Kim, Bobae Kim, Wilhelm H. Holzapfel, Chang-Kee Hyun, Nobuyuki Takahashi. Disturbance of lipid metabolism in germ-free mice transplanted with gut microbiota of DSS-induced colitis mice. PLOS ONE 2023; 18(2): e0280850 doi: 10.1371/journal.pone.0280850
|
| 23 |
Nayra Merino de Paz, Marta Carrillo-Palau, Alejandro Hernández-Camba, Pedro Abreu-González, Antonia de Vera-González, Alejandra González-Delgado, Candelaria Martín-González, Miguel Á. González-Gay, Iván Ferraz-Amaro. Association of Serum Malondialdehyde Levels with Lipid Profile and Liver Function in Patients with Inflammatory Bowel Disease. Antioxidants 2024; 13(10): 1171 doi: 10.3390/antiox13101171
|
| 24 |
Kamolyut Lapumnuaypol, Napatt Kanjanahattakij, David Pisarcik, Charat Thongprayoon, Karn Wijarnpreecha, Wisit Cheungpasitporn. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. European Journal of Gastroenterology & Hepatology 2018; 30(8): 854 doi: 10.1097/MEG.0000000000001144
|
| 25 |
Sutapa Sarkar, Diana Kimono, Muayad Albadrani, Ratanesh K. Seth, Philip Busbee, Hasan Alghetaa, Dwayne E. Porter, Geoff I. Scott, Bryan Brooks, Mitzi Nagarkatti, Prakash Nagarkatti, Saurabh Chatterjee. Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45009-1
|
| 26 |
Mark A. Febbraio, Michael Karin. “Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axis. Cell Metabolism 2021; 33(12): 2316 doi: 10.1016/j.cmet.2021.09.004
|
| 27 |
Sven H. Loosen, Münevver Demir, Karel Kostev, Tom Luedde, Christoph Roderburg. Incidences of hypothyroidism and autoimmune thyroiditis are increased in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e1008 doi: 10.1097/MEG.0000000000002136
|
| 28 |
Scott McHenry, Matthew Glover, Ali Ahmed, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Nicholas O Davidson, Parakkal Deepak. NAFLD Is Associated With Quiescent Rather Than Active Crohn’s Disease. Inflammatory Bowel Diseases 2024; 30(5): 757 doi: 10.1093/ibd/izad129
|
| 29 |
Mercedes Perez-Carreras, Begoña Casis-Herce, Raquel Rivera, Inmaculada Fernandez, Pilar Martinez-Montiel, Victoria Villena. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. World Journal of Gastroenterology 2021; 27(41): 7113-7124 doi: 10.3748/wjg.v27.i41.7113
|
| 30 |
Lívia dos Remédios Pamplona de Oliveira, Tarsila Campanha da Rocha Ribeiro, Carlos Alberto Mourao Junior, Maria Antônia de Lima Barra, Mariana Hippert Gonçalves Silva, Luis Pordeus Shafee, Sarah Mendes Zacarias, Lenilton da Costa Campos, Helena Maria Giordano Valério, Júlio Maria Fonseca Chebli. Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center. Revista da Associação Médica Brasileira 2024; 70(6) doi: 10.1590/1806-9282.20231321
|
| 31 |
Ludovico Abenavoli, Rocco Spagnuolo, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, Luigi Boccuto, Francesco Luzza. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study. Medicina 2023; 59(11): 1935 doi: 10.3390/medicina59111935
|
| 32 |
Sutapa Sarkar, Punnag Saha, Ratanesh K. Seth, Ayan Mondal, Dipro Bose, Diana Kimono, Muayad Albadrani, Avik Mukherjee, Dwayne E. Porter, Geoff I. Scott, Shuo Xiao, Bryan Brooks, John Ferry, Mitzi Nagarkatti, Prakash Nagarkatti, Saurabh Chatterjee. Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2020; 238: 108854 doi: 10.1016/j.cbpc.2020.108854
|
| 33 |
Alvin T George, Matthew Glover, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Scott McHenry, Parakkal Deepak. Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease. Crohn's & Colitis 360 2023; 5(1) doi: 10.1093/crocol/otad005
|
| 34 |
Wenjia Wang, Yiheng Han, Wen Yin, Qiaozhi Wang, Yi Wu, Maobo Du. Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1428327
|
| 35 |
Cátia Arieira, Sara Monteiro, Sofia Xavier, Francisca Dias de Castro, Joana Magalhães, Maria J. Moreira, Carla Marinho, José Cotter. Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. European Journal of Gastroenterology & Hepatology 2019; 31(8): 998 doi: 10.1097/MEG.0000000000001319
|
| 36 |
Rashida Ginwala, Raina Bhavsar, De Gaulle I. Chigbu, Pooja Jain, Zafar K. Khan. Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin. Antioxidants 2019; 8(2): 35 doi: 10.3390/antiox8020035
|
| 37 |
Ming Xie, Haokai Tang, Feifei Li, Si Wu, Yanhui Dong, Yide Yang, Julien Steven Baker, Jun Ma. Mediating Roles of hsCRP, TNF-α and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese Adults. Biology 2021; 10(9): 895 doi: 10.3390/biology10090895
|
| 38 |
Zhipeng Tao, My N. Helms, Benjamin C. B. Leach, Xu Wu. Molecular insights into the multifaceted functions and therapeutic targeting of high mobility group box 1 in metabolic diseases. Journal of Cellular and Molecular Medicine 2022; 26(14): 3809 doi: 10.1111/jcmm.17448
|
| 39 |
Mohammad Zamani, Shaghayegh Alizadeh‐Tabari, Siddharth Singh, Rohit Loomba. Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2022; 55(8): 894 doi: 10.1111/apt.16879
|
| 40 |
Beiying Deng, Yinghui Liu, Ying Chen, Pengzhan He, Jingjing Ma, Zongbiao Tan, Jixiang Zhang, Weiguo Dong. Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative colitis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-66574-0
|
| 41 |
Chiara Saroli Palumbo, Sophie Restellini, Che-Yung Chao, Achuthan Aruljothy, Carolyne Lemieux, Gary Wild, Waqqas Afif, Peter L Lakatos, Alain Bitton, Sila Cocciolillo, Peter Ghali, Talat Bessissow, Giada Sebastiani. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. Inflammatory Bowel Diseases 2019; 25(1): 124 doi: 10.1093/ibd/izy200
|
| 42 |
Sophie Restellini, Omar Kherad, Talat Bessissow, Charles Ménard, Myriam Martel, Maryam Taheri Tanjani, Peter L Lakatos, Alan N Barkun. Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease. World Journal of Gastroenterology 2017; 23(32): 5994-6002 doi: 10.3748/wjg.v23.i32.5994
|
| 43 |
Kandy T Velázquez, Reilly T Enos, Jackie E Bader, Alexander T Sougiannis, Meredith S Carson, Ioulia Chatzistamou, James A Carson, Prakash S Nagarkatti, Mitzi Nagarkatti, E Angela Murphy. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World Journal of Hepatology 2019; 11(8): 619-637 doi: 10.4254/wjh.v11.i8.619
|
| 44 |
Eleonora Cremonini, Ziwei Wang, Ahmed Bettaieb, Ana M. Adamo, Elena Daveri, David A. Mills, Karen M. Kalanetra, Fawaz G. Haj, Sidika Karakas, Patricia I. Oteiza. (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance. Redox Biology 2018; 14: 588 doi: 10.1016/j.redox.2017.11.002
|
| 45 |
Haluk Tarik KANI, İlknur DELIKTAS, Yusuf YILMAZ. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. Marmara Medical Journal 2019; 32(2): 68 doi: 10.5472/marumj.570907
|
| 46 |
Min Chen, Yanke Lin, Yongkang Dang, Yifei Xiao, Fugui Zhang, Guanghui Sun, Xuejun Jiang, Li Zhang, Jianhao Du, Shuyi Duan, Xiaojian Zhang, Zifei Qin, Jing Yang, Kaisheng Liu, Baojian Wu. Reprogramming of rhythmic liver metabolism by intestinal clock. Journal of Hepatology 2023; 79(3): 741 doi: 10.1016/j.jhep.2023.04.040
|
| 47 |
Iván Ferraz-Amaro, Alejandro Hernández-Camba, Marta Carrillo-Palau, Noemi Hernández Álvarez-Buylla, Antonia de Vera-González, Alejandra González-Delgado, Elena Heras-Recuero, Miguel Á. González-Gay. Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine 2024; 13(21): 6430 doi: 10.3390/jcm13216430
|
| 48 |
Varun Chandrashekaran, Ratanesh K. Seth, Diptadip Dattaroy, Firas Alhasson, Jacek Ziolenka, James Carson, Franklin G. Berger, Balaraman Kalyanaraman, Anna Mae Diehl, Saurabh Chatterjee. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease. Redox Biology 2017; 13: 8 doi: 10.1016/j.redox.2017.05.005
|
| 49 |
Kwang Il Seo, Sang-Bum Kang. Hepatobiliary Manifestation of Inflammatory Bowel Disease. The Korean Journal of Gastroenterology 2019; 73(5): 248 doi: 10.4166/kjg.2019.73.5.248
|
| 50 |
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis. Emerging concepts in non-invasive monitoring of Crohn’s disease. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818769076
|
| 51 |
Scott McHenry, Ankita Tirath, Richard Tsai, Yeshika Sharma, Avegail G Flores, Nicholas O Davidson, Kathryn J Fowler, Matthew A Ciorba, Parakkal Deepak. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2020; 26(12): 1917 doi: 10.1093/ibd/izz324
|
| 52 |
Andrew Szilagyi. Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms. Clinical Journal of Gastroenterology 2020; 13(2): 139 doi: 10.1007/s12328-019-01037-y
|
| 53 |
Rui Gaspar, Catarina Castelo Branco, Guilherme Macedo. Liver manifestations and complications in inflammatory bowel disease: A review. World Journal of Hepatology 2021; 13(12): 1956-1967 doi: 10.4254/wjh.v13.i12.1956
|
| 54 |
Macarena Klein, Paulina Núñez, Constanza Bay, Carolina Pizarro, Rocío Sedano, Rodrigo Quera. Liver Disorders in Inflammatory Bowel Disease. EMJ Hepatology 2020; : 26 doi: 10.33590/emjhepatol/20-00040
|
| 55 |
Yahav Eilam, Hamdan Khattib, Noam Pintel, Dorit Avni. Microalgae—Sustainable Source for Alternative Proteins and Functional Ingredients Promoting Gut and Liver Health. Global Challenges 2023; 7(5) doi: 10.1002/gch2.202200177
|
| 56 |
Zhiyuan Wei, Jiangbin Wang. Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1375654
|
| 57 |
Charalampia Amerikanou, Efstathia Papada, Aristea Gioxari, Ilias Smyrnioudis, Stamatia-Angeliki Kleftaki, Evdokia Valsamidou, Victoria Bruns, Rajarshi Banerjee, Maria Giovanna Trivella, Natasa Milic, Milica Medić-Stojanoska, Amalia Gastaldelli, Aimo Kannt, George V. Dedoussis, Andriana C. Kaliora. Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. Pharmacological Research 2021; 171: 105753 doi: 10.1016/j.phrs.2021.105753
|
| 58 |
Chang-Kee Hyun. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. International Journal of Molecular Sciences 2021; 22(17): 9139 doi: 10.3390/ijms22179139
|
| 59 |
Zixuan Zhong, Minxuan Xu, Chenxu Ge, Jun Tan. Exploring shared molecular signatures and regulatory mechanisms in nonalcoholic steatohepatitis and inflammatory bowel disease using integrative bioinformatics analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-62310-w
|
| 60 |
Zi-Yuan Zou, Bo Shen, Jian-Gao Fan. Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019; 25(11): 1764 doi: 10.1093/ibd/izz043
|
| 61 |
Jeonghyeon Kwon, Chungho Lee, Sungbaek Heo, Bobae Kim, Chang-Kee Hyun. DSS-induced colitis is associated with adipose tissue dysfunction and disrupted hepatic lipid metabolism leading to hepatosteatosis and dyslipidemia in mice. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-84761-1
|
| 62 |
Austin Lin, Hannah Roth, Adjoa Anyane-Yeboa, David T Rubin, Sonali Paul. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases 2021; 27(6): 947 doi: 10.1093/ibd/izaa189
|
| 63 |
Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang. Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease. Digestive Diseases 2020; 38(6): 507 doi: 10.1159/000506938
|
| 64 |
S. V. Okovity, K. L. Raikhelson, A. V. Volnukhin, D. A. Kudlai. Hepatoprotective properties of glycyrrhizic acid. Experimental and Clinical Gastroenterology 2020; (12): 96 doi: 10.31146/1682-8658-ecg-184-12-96-108
|
| 65 |
Rossella Maresca, Irene Mignini, Simone Varca, Valentin Calvez, Fabrizio Termite, Giorgio Esposto, Lucrezia Laterza, Franco Scaldaferri, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together. International Journal of Molecular Sciences 2024; 25(6): 3278 doi: 10.3390/ijms25063278
|
| 66 |
Antoine Boustany, Romy Rahhal, Jad Mitri, Somtochukwu Onwuzo, Hadi Khaled Abou Zeid, György Baffy, Myriam Martel, Alan N. Barkun, Imad Asaad. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review. European Journal of Gastroenterology & Hepatology 2023; 35(10): 1067 doi: 10.1097/MEG.0000000000002607
|
| 67 |
Rosellina Margherita Mancina, Daniele De Bonis, Raffele Pagnotta, Cristina Cosco, Vincenzo Cosco, Tiziana Montalcini, Arturo Pujia, Patrizia Doldo, Rocco Spagnuolo. Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis. Gastroenterology Nursing 2020; 43(4): 292 doi: 10.1097/SGA.0000000000000461
|
| 68 |
Shaghayegh Baradaran Ghavami, Hamid Asadzadeh Aghdaei, Dario Sorrentino, Shabnam Shahrokh, Maryam Farmani, Fatemeh Ashrafian, Maria Pina Dore, Shahrbanoo Keshavarz Azizi Raftar, Seyed Mobin Khoramjoo, Mohammad Reza Zali. Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?. International Journal of Molecular Sciences 2021; 22(15): 8274 doi: 10.3390/ijms22158274
|